Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000552 | 0.84 | KDM4E (0.69) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL2936345 | 0.81 | KMT2A (0.60) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL490691 | 0.80 | CTSG (0.56) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL29639215 | 0.79 | KMT2A (0.54) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL991380 | 0.79 | KMT2A (0.54) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL31711441 | 0.79 | KDM4E (0.60) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL8593262 | 0.78 | KDM4E (0.50) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL7495080 | 0.78 | ROCK2 (0.59) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL7885276 | 0.78 | CTSG (0.55) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL8879501 | 0.78 | BCHE (0.78) | KMT2AMEN1ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735055-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS | Curasight A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | TRT INNOVATIONS APS (DK) | 2026-03-31 | — | — | US | claimed |
| EP-4448020-B1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT AS (DK) | 2026-02-04 | — | — | EP | claimed |
| EP-4678194-A1 | THERAPEUTIC APPLICATION OF 64CU-LABELLED CONJUGATES FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-4651912-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | Curasight A/S (DK) | 2025-11-26 | — | — | EP | claimed |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | CURASIGHT AS (DK) | 2025-10-16 | — | — | US | claimed |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2025-09-09 | — | — | US | claimed |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT A/S (DK) | 2025-02-13 | — | — | US | claimed |
| WO-2025003190-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS | CURASIGHT A/S (DK) | 2025-01-02 | — | — | WO | claimed |
| EP-4448020-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | Curasight A/S (DK) | 2024-10-23 | — | — | EP | claimed |
| CN-118695877-A | Urokinase-type plasminogen activator receptor (UPAR) -PET/CT in neuroendocrine tumors | 库拉赛特股份公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2024153756-A1 | RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING | CURASIGHT A/S (DK) | 2024-07-25 | — | — | WO | claimed |
| EP-3590542-B1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT AS (DK) | 2024-01-03 | — | — | EP | claimed |
| WO-2023111176-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | CURASIGHT A/S (DK) | 2023-06-22 | — | — | WO | claimed |
| EP-4197561-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | Curasight A/S (DK) | 2023-06-21 | — | — | EP | claimed |
| WO-2023099472-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | CURASIGHT A/S (DK) | 2023-06-08 | — | — | WO | claimed |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | CURASIGHT A/S (DK) | 2022-06-30 | — | — | US | claimed |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | CURASIGHT A/S (DK) | 2022-04-26 | — | — | US | claimed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | claimed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589171-B2 | 177-Lu labeled peptide for site-specific uPAR-targeting | LNPEP, XPNPEP2, PLAUR | KMT2A 599/4885MEN1 1350/4885ATM 2484/4885 |
| US-20220202966-A1 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | PLAUR, PLAU, SERPINE1 | KMT2A 3450/4885MEN1 1189/4885ATM 3212/4885 |
| US-12409240-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | KMT2A 3450/4885MEN1 1189/4885ATM 3212/4885 |
| US-11311637-B2 | Positron emitting radionuclide labeled peptides for human uPAR PET imaging | PLAUR, PLAU, SERPINE1 | KMT2A 3450/4885MEN1 1189/4885ATM 3212/4885 |
| US-20250049971-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS | PLAUR, PLAU, PROKR1 | KMT2A 1151/4885MEN1 122/4885ATM 4274/4885 |
| US-20250319215-A1 | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCCS) | PLAUR, PLAU, SERPINE1 | KMT2A 1338/4885MEN1 811/4885ATM 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.